Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Hypofractionated irradiation in 794 elderly breast cancer patients: An observational study.

La Rocca E, Meneghini E, Dispinzieri M, Fiorentino A, Bonfantini F, Di Cosimo S, Gennaro M, Cosentino V, Sant M, Pignoli E, Valdagni R, Lozza L, De Santis MC.

Breast J. 2019 Aug 25. doi: 10.1111/tbj.13489. [Epub ahead of print]

PMID:
31448501
2.

High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer.

Gennaro M, Meneghini E, Baili P, Bravaccini S, Curcio A, De Santis MC, Lozza L, Listorti C, Di Cosimo S, Sant M, Folli S.

Tumori. 2019 Aug 26:300891619867845. doi: 10.1177/0300891619867845. [Epub ahead of print]

PMID:
31446852
3.

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.

Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F.

PLoS One. 2019 Aug 7;14(8):e0220644. doi: 10.1371/journal.pone.0220644. eCollection 2019.

4.

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber RD, Piccart-Gebhart M, Di Cosimo S.

Eur J Cancer. 2019 Sep;118:169-177. doi: 10.1016/j.ejca.2019.04.038. Epub 2019 Aug 1.

PMID:
31377477
5.

Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients.

De Santis MC, La Rocca E, Meneghini E, Bregni G, Di Lorenzo G, Galli G, Di Nicola M, Folli S, Gennaro M, Pruneri G, Paolini B, Daidone MG, De Braud F, Apolone G, Sant M, Di Cosimo S.

Clin Transl Oncol. 2019 Aug 1. doi: 10.1007/s12094-019-02188-7. [Epub ahead of print]

PMID:
31372896
6.

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E.

Eur J Cancer. 2019 Sep;118:1-9. doi: 10.1016/j.ejca.2019.06.001. Epub 2019 Jul 5.

7.

RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Di Cosimo S, Torri V, Porcu L.

J Natl Cancer Inst. 2019 Jun 11. pii: djz092. doi: 10.1093/jnci/djz092. [Epub ahead of print] No abstract available.

PMID:
31187132
8.

Interobserver variability (between radiation oncologist and radiation therapist) in tumor bed contouring after breast-conserving surgery.

La Rocca E, Lici V, Giandini T, Bonfantini F, Frasca S, Dispinzieri M, Gennaro M, S DC, Di Cosimo S, Lozza L, Pignoli E, Valdagni R, De Santis MC.

Tumori. 2019 Jun;105(3):210-215. doi: 10.1177/0300891619839288. Epub 2019 Mar 27.

PMID:
30915903
9.

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M.

Clin Cancer Res. 2019 Jun 15;25(12):3581-3588. doi: 10.1158/1078-0432.CCR-18-2521. Epub 2019 Mar 12.

PMID:
30862692
10.

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.

Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Peña L, Izquierdo M, Huober J, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Daidone MG.

Clin Cancer Res. 2019 Jul 1;25(13):3887-3895. doi: 10.1158/1078-0432.CCR-18-2507. Epub 2019 Feb 27.

PMID:
30814109
11.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J.

Ann Oncol. 2019 Jul 1;30(7):1179. doi: 10.1093/annonc/mdy535. No abstract available.

PMID:
30624662
12.

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S.

Ann Oncol. 2019 Jul 1;30(7):1178. doi: 10.1093/annonc/mdy534. No abstract available.

PMID:
30624599
13.

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.

Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E.

Br J Cancer. 2018 Dec;119(12):1487-1494. doi: 10.1038/s41416-018-0318-0. Epub 2018 Nov 27.

14.

Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer.

La Rocca E, Dispinzieri M, Lozza L, Mariani G, Di Cosimo S, Gennaro M, Valdagni R, De Santis MC.

Med Oncol. 2018 Nov 15;36(1):4. doi: 10.1007/s12032-018-1228-y.

PMID:
30443687
15.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M.

Cytokine Growth Factor Rev. 2018 Dec;44:1-10. doi: 10.1016/j.cytogfr.2018.10.005. Epub 2018 Oct 30.

PMID:
30393044
16.

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber RD, de Azambuja E, Ignatiadis M.

Cancer. 2019 Jan 15;125(2):307-316. doi: 10.1002/cncr.31784. Epub 2018 Oct 18.

PMID:
30335191
17.

Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy.

Dispinzieri M, La Rocca E, Meneghini E, Fiorentino A, Lozza L, Di Cosimo S, Gennaro M, Cosentino V, Sant M, Pignoli E, Valdagni R, Bonfantini F, De Santis MC.

Med Oncol. 2018 Jun 16;35(7):107. doi: 10.1007/s12032-018-1165-9.

PMID:
29907919
18.

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C.

JAMA Oncol. 2018 Nov 1;4(11):e181564. doi: 10.1001/jamaoncol.2018.1564. Epub 2018 Nov 8.

19.

Hypofractionated Whole-Breast Irradiation With or Without Boost in Elderly Patients: Clinical Evaluation of an Italian Experience.

De Santis MC, Bonfantini F, Di Salvo F, Fiorentino A, Dispinzieri M, Caputo M, Di Cosimo S, Mariani G, Gennaro M, Cosentino V, Sant M, Pignoli E, Valdagni R, Lozza L.

Clin Breast Cancer. 2018 Oct;18(5):e1059-e1066. doi: 10.1016/j.clbc.2018.04.003. Epub 2018 Apr 22.

PMID:
29773414
20.

Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patients.

Gennaro M, Di Cosimo S, Ardoino I, Veneroni S, Mariani L, Agresti R, Daidone MG, de Braud F, Apolone G, Biganzoli E, Demicheli R.

Breast. 2018 Aug;40:131-135. doi: 10.1016/j.breast.2018.05.004. Epub 2018 May 14.

21.

Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer.

Galli G, Bregni G, Cavalieri S, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis MC, Paolini B, Carcangiu ML, de Braud F, Di Cosimo S.

Breast Care (Basel). 2017 Dec;12(6):391-394. doi: 10.1159/000479582. Epub 2017 Dec 12.

22.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E.

Breast Cancer Res Treat. 2018 Apr;168(3):631-638. doi: 10.1007/s10549-017-4628-3. Epub 2017 Dec 27.

23.

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja E.

Eur J Cancer. 2018 Jan;89:42-48. doi: 10.1016/j.ejca.2017.10.036. Epub 2017 Dec 8.

24.

Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?

De Santis MC, Bonfantini F, Di Salvo F, Fiorentino A, Riboldi VM, Di Cosimo S, Bianchi GV, Gennaro M, Cosentino V, Sant M, Pignoli E, Valdagni R, Lozza L.

Clin Breast Cancer. 2018 Jun;18(3):e363-e371. doi: 10.1016/j.clbc.2017.08.011. Epub 2017 Aug 24.

PMID:
28958838
25.

Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast.

Gennaro M, De Santis MC, Mariani L, Lo Vullo S, Cappelletti V, Agresti R, Cortinovis U, Paolini B, Di Cosimo S, Carcangiu ML, Daidone MG, Lozza L.

Breast. 2017 Oct;35:63-68. doi: 10.1016/j.breast.2017.06.010. Epub 2017 Jun 23.

26.

How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.

Appierto V, Di Cosimo S, Reduzzi C, Pala V, Cappelletti V, Daidone MG.

Semin Cancer Biol. 2017 Jun;44:106-116. doi: 10.1016/j.semcancer.2017.04.007. Epub 2017 Apr 22. Review.

PMID:
28442298
27.

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E.

J Clin Oncol. 2017 May 1;35(13):1421-1429. doi: 10.1200/JCO.2016.69.7722. Epub 2017 Mar 13.

28.

Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history.

Galli G, Tessari A, Di Cosimo S.

Breast Cancer. 2017 May;24(3):491-492. doi: 10.1007/s12282-017-0766-z. Epub 2017 Mar 6. No abstract available.

PMID:
28265812
29.

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.

Gevorgyan A, Bregni G, Galli G, Zanardi E, de Braud F, Di Cosimo S.

Breast Care (Basel). 2016 Dec;11(6):424-426. doi: 10.1159/000453572. Epub 2016 Dec 9.

30.

Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.

Galli G, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, Gennaro M, De Santis MC, Lozza L, de Braud F, Di Cosimo S.

Breast Cancer. 2017 Jul;24(4):635-641. doi: 10.1007/s12282-017-0751-6. Epub 2017 Jan 5.

PMID:
28058615
31.

Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.

Petrelli F, Barni S, Bregni G, de Braud F, Di Cosimo S.

Breast Cancer Res Treat. 2016 Dec;160(3):425-437. doi: 10.1007/s10549-016-4025-3. Epub 2016 Oct 21. Review.

PMID:
27770282
32.

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C.

JAMA Oncol. 2017 Feb 1;3(2):227-234. doi: 10.1001/jamaoncol.2016.3824.

33.

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.

Morancho B, Zacarías-Fluck M, Esgueva A, Bernadó-Morales C, Di Cosimo S, Prat A, Cortés J, Arribas J, Rubio IT.

Oncotarget. 2016 Oct 18;7(42):67956-67965. doi: 10.18632/oncotarget.11815.

34.

Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.

De Santis MC, Bonfantini F, Di Salvo F, Dispinzieri M, Mantero E, Soncini F, Baili P, Sant M, Bianchi G, Maggi C, Di Cosimo S, Agresti R, Pignoli E, Valdagni R, Lozza L.

Breast. 2016 Oct;29:90-5. doi: 10.1016/j.breast.2016.07.013. Epub 2016 Jul 29.

35.

Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.

Petrelli F, Di Cosimo S, Lonati V, Barni S.

Clin Breast Cancer. 2016 Oct;16(5):327-334. doi: 10.1016/j.clbc.2016.05.002. Epub 2016 May 13. Review.

PMID:
27282844
36.

Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer.

Gevorgyan A, Bregni G, Galli G, Ganzinelli M, Martinetti A, Lo Vullo S, Mariani L, Festinese F, Sottotetti E, de Braud F, Di Cosimo S.

Tumori. 2016 Aug 3;102(4):e11-4. doi: 10.5301/tj.5000515.

PMID:
27174629
37.

Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer.

Di Cosimo S, Bregni G, Daidone MG, Cinquini M, de Braud F, Torri V.

Breast. 2016 Jun;27:187-8. doi: 10.1016/j.breast.2016.02.002. Epub 2016 Apr 23. No abstract available.

38.

Axillary coverage by whole breast irradiation in 1 to 2 positive sentinel lymph nodes in breast cancer patients.

De Santis MC, Bonfantini F, Dispinzieri M, Meroni S, Diletto B, Mantero ED, Franceschini M, Soncini F, Di Cosimo S, Cosentino V, Pignoli E, Lozza L.

Tumori. 2016 Aug 3;102(4):409-13. doi: 10.5301/tj.5000482. Epub 2016 Mar 16.

PMID:
27002946
39.

Role of patient and tumor characteristics in sentinel lymph node metastasis in patients with luminal early breast cancer: an observational study.

La Verde N, Biagioli E, Gerardi C, Cordovana A, Casiraghi C, Floriani I, Bernardin E, Farina G, Di Cosimo S, Dazzani MC, Gherardi G.

Springerplus. 2016 Feb 3;5:114. doi: 10.1186/s40064-016-1720-9. eCollection 2016.

40.

Better Together: Targeted Combination Therapies in Breast Cancer.

Zanardi E, Bregni G, de Braud F, Di Cosimo S.

Semin Oncol. 2015 Dec;42(6):887-95. doi: 10.1053/j.seminoncol.2015.09.029. Epub 2015 Sep 24. Review.

PMID:
26615133
41.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):356.

42.

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J.

Breast Cancer Res Treat. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4.

43.

Trastuzumab cardiac toxicity: a problem we put our heart into.

Bregni G, Galli G, Gevorgyan A, de Braud F, Di Cosimo S.

Tumori. 2016 Jan-Feb;102(1):1-5. doi: 10.5301/tj.5000393. Epub 2015 Jul 30. Review.

PMID:
26350178
44.

Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer.

Fina E, Reduzzi C, Motta R, Di Cosimo S, Bianchi G, Martinetti A, Wechsler J, Cappelletti V, Daidone MG.

Int J Biol Markers. 2015 Nov 11;30(4):e429-33. doi: 10.5301/jbm.5000166.

PMID:
26349664
45.

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.

Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E.

Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405.

46.

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):90-6. doi: 10.1093/jncimonographs/lgv023.

47.

Prognosis of women with early breast cancer and PIK3CA mutations.

Di Cosimo S, Bianchi GV, Bregni G, de Braud F.

Breast. 2015 Jun;24(3):283-4. doi: 10.1016/j.breast.2015.02.028. Epub 2015 Mar 12. No abstract available.

48.

Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.

Serpico D, Porcu L, Tessari A, Gevorgyan A, Bregni G, Galli G, de Braud F, Torri V, Di Cosimo S.

Clin Transl Oncol. 2015 Jul;17(7):530-8. doi: 10.1007/s12094-015-1274-2. Epub 2015 Jan 21.

PMID:
25604128
49.

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.

Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Braña I, Roda D, Haines BB, Zhang T, Winter CG, Jha S, Xu Y, Frazier J, Klinghoffer RA, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J.

Clin Cancer Res. 2015 Jan 1;21(1):49-59. doi: 10.1158/1078-0432.CCR-14-0940. Epub 2014 Oct 15.

50.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J.

Lancet Oncol. 2014 Sep;15(10):1137-46. doi: 10.1016/S1470-2045(14)70320-1. Epub 2014 Aug 14.

PMID:
25130998

Supplemental Content

Loading ...
Support Center